GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

By Dr. Sushama R. Chaphalkar, PhD. Prescriptions of GLP-1RAs and SGLT2 inhibitors in type 1 diabetes patients rose from 2010 ...

GLP-1 receptor agonists do not affect cardiovascular, kidney, or safety outcomes regardless of SGLT2 inhibitor use in patients with type 2 diabetes.

About The Study: Prescribing for both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in a type 1 diabetes (T1D) population identified in a ...

Additionally, nearly one-quarter had heart failure and 49% were taking an sodium-glucose cotransporter 2 (SGLT2) inhibitor at ...

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

TheracosBio has entered a partnership with BAMCO Africa to deliver BRENZAVVY (bexagliflozin) to patients in sub-Saharan ...

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.

Background: Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. The sodium glucose-co-transporter-2 ...

After Viatris’ CEO earlier this year promised to be “opportunistic” about future business development moves, the company is ...

TheracosBio and BAMCO Africa, Inc. today announced they have partnered to bring BRENZAVVY® (bexagliflozin), an FDA-approved ...